The position 473 of SMO was also found in association with a glycine substitution (D473G) in other studies on BCC [78,85], in agreement with the observation that the substitution of D473 with any other amino acid is responsible for reduced affinity of vismodegib for its target SMO [66]. The gene discussed is SMO; the disease is skin basal cell carcinoma.